GarudaBio is an oncology focused biotechnology company developing a unique approach to monoclonal antibody targeting of drug resistant, aggressive cancers that express integrin αvβ3. The company’s antibody based immunotherapy links the key oncogenic cancer cell target, integrin αvβ3, to engagement of tumor associated macrophages to kill αvβ3+ cancer cells. Compelling preclinical proof of concept has been demonstrated in lung cancers resistant to EGFR targeted therapies and αvβ3+ KRAS mutant addicted cancers (lung and pancreatic adenocarcinoma).